Inovio: First subject dosed with DNA-encoded monoclonal antibody technology
Inovio Pharmaceuticals, in collaboration with The Wistar Institute and the University of Pennsylvania announced that the first subject was dosed as part of the first-ever human study of Inovio's DNA-encoded monoclonal antibody technology. Funded fully by the Bill & Melinda Gates Foundation, this trial's focus is on evaluating the dMAb's ability to prevent or treat Zika virus infection. The clinical results will also help to broadly advance Inovio's dMAb programs in infectious diseases and cancer. When delivered directly into the body, the genetic codes provided by the synthetic dMAbs, instruct the body's cells to become the factory which manufactures the therapeutic antibody products, enabling a major leap forward in antibody technology.